Censa Pharmaceuticals is dedicated to developing and commercializing novel therapies for people living with orphan and non-orphan metabolic and CNS diseases associated with defects in the tetrahydrobiopterin bio-chemical pathways. Censa’s initial focus is on phenylketonuria and primary BH4 deficiency with a longer term plan to address broader neuropsychiatric and neurodegenerative disorders such as Autism, Schizophrenia, Bipolar and Parkinson’s disease.